HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US COVID-19 Fraud: IV Drip Provider Reconsiders Claims, Bee Honey Joins List Of Unapproved Cures

Executive Summary

New York business reconsiders claiming intravenous drips of vitamin blends prevent COVID-19 infections after industry group forwarded concerns to regulators. Latest natural health remedy linked to fraudulent COVID-19 treatment claims is honey from marketers’ beehives.

You may also be interested in...



US COVID-19 Fraud: Avenova Eyelid, Eyelash Cleanser Spray Latest Target Of FDA, FTC Warning

Federal agencies submitted joint warning to NovaBay after reviewing its website and social media pages for its Avenova (hypochlorous acid 0.01%) spray solution.

US FDA’s 30-Day Extension For Nitrosamine Assessments Short Of Industry Recommendation

Revision to FDA's September 2020 guidance on assessing nitrosamine impurity risks associated with all chemically synthesized APIs and all approved drug products that contain those APIs doesn’t satisfy industry stakeholders.

With Timetable In Hand And Icahn On Board, Bausch Health Looks To ‘Expedite Spin-Off’

Executives say Bausch + Lomb spin-out preparations will be completed by the end of Q3. When asked, they elaborated on Carl Icahn’s acquisition of 27.8m shares, for a 7.8% stake, and expansion of the firm’s board by two seats for Icahn’s representatives.

Topics

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel